

Gedeon Richter Plc. signed a license and distribution agreement with Bayer HealthCare

Budapest, Hungary – 27 January 2015 – Gedeon Richter Plc. (hereinafter: “Richter”) today announced that it has entered into a license and distribution agreement with Bayer HealthCare (hereinafter: “Bayer”) to commercialize the low dose gestodene and ethinyl-estradiol containing transdermal contraceptive patch of Bayer in the European Union, in other European countries and also in certain Latin American countries under the trademark of Lisvy[®]. National marketing authorizations have been gradually granted in the majority of European countries following the approval in the European Union in the first quarter 2014.

Under the terms of the agreement Richter shall make an upfront payment upon signature of the contract, and further milestone payments shall be made depending on the progress of the commercialization of the product. In addition, further sales related royalties will become payable to Bayer subsequent to the launch of the product.

In line with the agreement Richter shall be responsible for conducting and funding the PASS Study (Post-Authorisation Safety Study), as required by the European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC).

“We remain committed to the development and commercialization of female healthcare products aiming towards the improvement of the quality of life for the female population in all age groups. This agreement is considered as a further step to enhance our existing branded female healthcare franchise worldwide, being a paramount strategic initiative for our Company”, stated Erik Bogsch, Managing Director of Gedeon Richter Plc.

“As a leading company in hormonal contraception we have a rich portfolio in short-term, long-term and permanent contraceptive choices for women. However in order to realize the full potential of the female contraceptive patch we have decided to partner with Gedeon Richter, who will cover Region Europe and certain countries in Latin America”, said Scott Sherriff, Head of Women's Healthcare, Bayer HealthCare Pharmaceuticals.

About Gedeon Richter

Gedeon Richter Plc. (www.richter.hu), headquartered in Budapest/Hungary, is a major pharmaceutical company in Central Eastern Europe, with an expanding direct presence in Western Europe. Richter's consolidated sales were approximately EUR1.2 billion (US\$1.6 billion) while its market capitalization amounted to EUR2.8 billion (US\$3.8 billion) in 2013. The product portfolio of Richter covers almost all important therapeutic areas, including gynaecology, central nervous system, and cardiovascular areas. Having the largest R&D unit in Central Eastern Europe, Richter's original research activity focuses on CNS disorders. With its widely acknowledged steroid chemistry expertise, Richter is a significant player in the female healthcare field worldwide. Richter is also active in biosimilar product development.

For further information:

Katalin Ördög, Investor Relations	+36 1 431 5680
Tamás Tomecskó, Public Relations	+36 1 505 7421